Driehaus Capital Management Reduces Stake in Crinetics Pharmaceuticals to 6.11%

Driehaus Capital Management LLC (DCM) filed a Schedule 13G/A on May 15, 2026, disclosing a reduction in its position in Crinetics Pharmaceuticals, Inc. (CRNX). As of the event date of March 31, 2026, the firm reported beneficial ownership of 6,395,922 shares of common stock, representing a 6.11% ownership stake. This reflects a decrease from the 7.54% ownership reported as of December 31, 2023. The filings indicate that DCM, acting as an investment adviser, holds these shares on a fully discretionary basis across numerous client accounts. DCM shares both voting and dispositive power over the reported shares. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. No individual client account managed by DCM is known to have an interest exceeding 5% of the class. The total value of the holdings is estimated at approximately $235.18 million based on recent market data.